Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series
Hematologic Oncology Update
00:00
Bone Targeted Agents for Multiple Myeloma
The MRC 9 trial, which is now several years old, did teach us that because they did take everybody with or without bone disease. So I would suggest that everybody who has symptomatic multiple myeloma requiring treatment should be on a bone targeted agent. Incidentally, Charles in the chat room said he's absolutely seen the upscopole effect in a CLL patient.
Transcript
Play full episode
